Trial Profile
A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 06 Apr 2022 This trial has been completed in Netherlands (End Date: 10 Nov 2017) according to European Clinical Trials Database record.
- 23 Mar 2020 Results published in the Clinical Infectious Diseases
- 07 Oct 2018 Results presented at the IDWeek 2018